Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8981350 | 1.00 | FAAH (0.39) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL8980908 | 1.00 | FAAH (0.39) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL550992 | 1.00 | FAAH (0.39) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL496169 | 1.00 | FAAH (0.39) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL76966 | 0.98 | BTK (0.38) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL202837 | 0.95 | BTK (0.38) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL142219 | 0.91 | MEN1 (0.39) | BTKGAAMEN1KMT2AMAPK1 | |
| SCHEMBL27646197 | 0.87 | GAA (0.37) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL15116645 | 0.86 | GAA (0.36) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL2789711 | 0.85 | GHSR (0.37) | FAAHBTKGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024177984-A1 | BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-11866422-B2 | Carbocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2024-01-09 | — | — | US | disclosed |
| US-11267803-B2 | Carbocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210347762-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-11091465-B2 | — | — | 2021-08-17 | — | — | US | disclosed |
| US-20200385362-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3472151-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017222914-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017044899-A1 | SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2017-03-16 | — | — | WO | disclosed |
| EP-2120965-B1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS INC (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8415497-B2 | N-halogenated amino compounds and derivatives | NOVABAY PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| WO-2011154677-A1 | SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL] 1-AMINOCYCLOALK-1-YLCARBOXAMIDE COMPOUNDS - 760 | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | WO | disclosed |
| EP-2271346-A2 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2009120652-A2 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-5543414-A | VIRICIDES | SYNTEX (USA) INC. (US) | 1996-08-06 | — | — | US | disclosed |
| US-5175146-A | Improved potency; storage stability; nonhydrolyzing; osteoporosis; Paget's disease; hypocalcemic | VICAL, INC. (US) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | FAAH 703/4885BTK 4274/4885GAA 2437/4885 |
| US-11267803-B2 | Carbocyclic prolinamide derivatives | HTRA1, ADCYAP1R1, HTRA2 | FAAH 703/4885BTK 4274/4885GAA 2437/4885 |
| US-20200385362-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | FAAH 703/4885BTK 4274/4885GAA 2437/4885 |
| US-11866422-B2 | Carbocyclic prolinamide derivatives | HTRA1, ADCYAP1R1, HTRA2 | FAAH 703/4885BTK 4274/4885GAA 2437/4885 |
| US-11091465-B2 | — | HTRA1, ALDH1A2, ADCYAP1R1 | FAAH 860/4885BTK 4263/4885GAA 1699/4885 |
| US-20210347762-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | FAAH 703/4885BTK 4274/4885GAA 2437/4885 |
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | DCTD, DDC, DAO | FAAH 2247/4885BTK 1477/4885GAA 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.